For research use only. Not for therapeutic Use.
AB928(CAT: I017795) is a small-molecule dual antagonist of the A2a and A2b adenosine receptors that is being developed as a potential immunotherapy for various types of cancer. Adenosine is a signaling molecule that plays a key role in regulating immune responses. By blocking the A2a and A2b adenosine receptors, AB928 can enhance the activity of immune cells, such as T cells and natural killer cells, and promote anti-tumor immunity. AB928 has shown promising results in preclinical and clinical studies, both as a monotherapy and in combination with other immunotherapies, such as checkpoint inhibitors.
| Catalog Number | I017795 |
| CAS Number | 2239273-34-6 |
| Molecular Formula | C₂₃H₂₂N₈O |
| Purity | ≥95% |
| Target | Adenosine Receptor |
| Reference | [1]. Seitz L, et al. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Invest New Drugs. 2019 Aug;37(4):711-721.<br>[2]. Daniel DiRenzo, et al. AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression [abstract]. |
